TY - JOUR T1 - Clinical presentation, disease course and outcome of COVID-19 in hospitalized patients with and without pre-existing cardiac disease – a cohort study across eighteen countries JF - medRxiv DO - 10.1101/2021.03.11.21253106 SP - 2021.03.11.21253106 AU - CAPACITY-COVID collaborative consortium and LEOSS Study Group AU - M Linschoten AU - A Uijl AU - A Schut AU - CEM Jakob AU - LR Romão AU - RM Bell AU - E McFarlane AU - M Stecher AU - AGM Zondag AU - EPA van Iperen AU - W Hermans-van Ast AU - NC Lea AU - J Schaap AU - LS Jewbali AU - PC Smits AU - RS Patel AU - A Aujayeb AU - DP Ripley AU - M Saxena AU - C Spinner AU - GP McCann AU - AJ Moss AU - E Parker AU - S Borgmann AU - E Tessitore AU - S Rieg AU - MT Kearney AU - R Byrom-Goulthorp AU - M Hower AU - AK Al-Ali AU - AM Alshehri AU - AN Alnafie AU - M Alshahrani AU - YA Almubarak AU - FA Al-Muhanna AU - AM Al-Rubaish AU - F Hanses AU - AC Shore AU - C Ball AU - CM Anning AU - MM Rüthrich AU - PR Nierop AU - MJGT Vehreschild AU - SRB Heymans AU - MTHM Henkens AU - AG Raafs AU - ICC van der Horst AU - BCT van Bussel AU - FJH Magdelijns AU - J Lanznaster AU - PY Kopylov AU - OV Blagova AU - K Wille AU - YM Pinto AU - JA Offerhaus AU - H Bleijendaal AU - C Piepel AU - JM ten Berg AU - WL Bor AU - M Maarse AU - C Römmele AU - RA Tio AU - NH Sturkenboom AU - L Tometten AU - CA den Uil AU - NTB Scholte AU - AL Groenendijk AU - S Dolff AU - LE Zijlstra AU - AD Hilt AU - M von Bergwelt-Baildon AU - BE Groenemeijer AU - U Merle AU - PM van der Zee AU - EA van Beek AU - K Rothfuss AU - FVY Tjong AU - ACJ van der Lingen AU - MZH Kolk AU - N Isberner AU - PS Monraats AU - M Magro AU - WRM Hermans AU - M Kochanek AU - G Captur AU - RJ Thomson AU - S Nadalin AU - GCM Linssen AU - T Veneman AU - R Zaal AU - C Degenhardt AU - FMAC Martens AU - EA Badings AU - R Strauss AU - AG Zaman AU - M Alkhalil AU - S Prasad AU - B Grüner AU - HE Haerkens-Arends AU - L Eberwein AU - P Dark AU - D Lomas AU - J vom Dahl AU - DO Verschure AU - K Hellwig AU - A Mosterd AU - D Rauschning AU - DJ van der Heijden AU - M Neufang AU - M van Hessen AU - C Raichle AU - L Montagna AU - SG Mazzilli AU - M Bianco AU - T Westhoff AU - A Shafiee AU - B Hedayat AU - E Saneei AU - H Porhosseini AU - B Jensen AU - L Gabriel AU - AG Er AU - BLJH Kietselaer AU - J Schubert AU - P Timmermans, Jr AU - P Messiaen AU - A Friedrichs AU - FS van den Brink AU - P Woudstra AU - J Trauth AU - MIA Ribeiro AU - K de With AU - MMJM van der Linden AU - JT Kielstein AU - R Macías Ruiz AU - W Guggemos AU - E Hellou AU - P Markart AU - HAM van Kesteren AU - D Heigener AU - JK de Vries AU - S Stieglitz AU - JB Baltazar AU - I Voigt AU - DJ van de Watering AU - M Milovanovic AU - J Redón AU - MJ Forner AU - J Rüddel AU - KW Wu AU - J Nattermann AU - LI Veldhuis AU - ICD Westendorp AU - C Riedel AU - JM Kwakkel-van Erp AU - S van Ierssel AU - EM van Craenenbroeck AU - L Walter AU - J de Sutter AU - M Worm AU - JT Drost AU - A Moriarty AU - R Salah AU - N Charlotte AU - AJM van Boxem AU - HGR Dorman AU - AC Reidinga AU - P van der Meer AU - E Wierda AU - HPAA van Veen AU - CE Delsing AU - MFL Meijs AU - RMA van de Wal AU - C Weytjens AU - RS Hermanides AU - ME Emans AU - NYY al-Windy AU - AMH Koning AU - DAAM Schellings AU - RL Anthonio AU - C Bucciarelli-Ducci AU - M Caputo AU - PHM Westendorp AU - AFM Kuijper AU - CEE van Ofwegen-Hanekamp AU - AM Persoon AU - J Seelig AU - P van der Harst AU - HJ Siebelink AU - M van Smeden AU - S Williams AU - L Pilgram AU - WH van Gilst AU - RG Tieleman AU - B Williams AU - FW Asselbergs Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/07/06/2021.03.11.21253106.abstract N2 - Aims Patients with cardiac disease are considered high risk for poor outcomes following hospitalization with COVID-19. The primary aim of this study was to evaluate heterogeneity in associations between various heart disease subtypes and in-hospital mortality.Method and results We used data from the CAPACITY-COVID registry and LEOSS study. Multivariable Poisson regression models were fitted to assess the association between different types of pre-existent heart disease and in-hospital mortality. 16,511 patients with COVID-19 were included (21.1% aged 66 – 75 years; 40.2% female) and 31.5% had a history of heart disease. Patients with heart disease were older, predominantly male and often had other comorbid conditions when compared to those without. Mortality was higher in patients with cardiac disease (29.7%; n=1545 versus 15.9%; n=1797). However, following multivariable adjustment this difference was not significant (adjusted risk ratio (aRR) 1.08 [95% CI 1.02 – 1.15; p-value 0.12 (corrected for multiple testing)]). Associations with in-hospital mortality by heart disease subtypes differed considerably, with the strongest association for heart failure aRR (1.19 [1.10 – 1.30]; p-value <0.018) particularly for severe NYHA III/IV) heart failure (aRR 1.41 [95% CI 1.20 – 1.64; p-value <0.018]. None of the other heart disease subtypes, including ischemic heart disease, remained significant after multivariable adjustment. Serious cardiac complications were diagnosed in <1% of patients.Conclusion Considerable heterogeneity exists in the strength of association between heart disease subtypes and in-hospital mortality. Of all patients with heart disease, those with heart failure are at greatest risk of death when hospitalized with COVID-19. Serious cardiac complications are rare.Competing Interest StatementThe following authors report support in the context of the present manuscript: Asselbergs FW: The University Medical Center Utrecht received grant funding from the Dutch Heart Foundation for conducting the CAPACITY-COVID registry (2020B006 CAPACITY). Kopylov PY: Sechenov University received funding by the Ministry of Science and Higher Education of the Russian Federation within the framework of state support for the creation and development of World-Class Research Center Digital Biodesign and Personalized Healthcare: No. 075-15-2020-926. Linschoten M: Reports support by the Alexandre Suerman Stipend of the University Medical Center Utrecht. McCann GP: Received grant funding as co-applicant for COVID Heart and PHOSP COVID research studies. Pilgram L: Received grant funding from the Willy Robert Pitzer Foundation during the conduct of the LEOSS registry study. Schut A: Werkgroep Cardiologische Centra Nederland (WCN), a partner within the CAPACITY-COVID consortium, has received funding from the Dutch Heart Foundation (2020B006 CAPACITY) for site management and logistic support in the context of the CAPACITY-COVID registry in the Netherlands. Shore AC: Received grant funding from the National Institute of Health Research for Exeter Clinical Research facility during the conduct of the study.Funding StatementThis work was supported by the Dutch Heart Foundation (2020B006 CAPACITY), the EuroQol Research Foundation, Novartis Global, Novo Nordisk Nederland, Servier Nederland and Daiichi Sankyo Nederland (CAPACITY-COVID) and the German Centre for Infection Research (DZIF) and the Willy Robert Pitzer Foundation (LEOSS). The work of Philippe Kopylov and Daria Gognieva was financed by the Ministry of Science and Higher Education of the Russian Federation within the framework of state support for the creation and development of World-Class Research Center Digital biodesign and personalized healthcare no. 075-15-2020-926.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ethics entity of the lead center of CAPACITY-COVID (Medical Research Ethics Committee Utrecht) deemed that the Medical Research Involving Human Subjects Act (WMO) does not apply to this study and therefore an official approval of this study by the MREC Utrecht was not required under the WMO (reference number WAG/avd/20/010579).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data underlying this article cannot be shared publicly for the privacy of individuals that participated in the study. The data will be shared on reasonable request to the corresponding author. ER -